ABSTRACT We have reported elsewhere that offspring from the No. 65 female of Xenopus laevis cleaved normally, but their development was arrested at the onset of gastrulation, like the Ambystoma ova-deficient (o) mutant, irrespective of mating with different wild-type males, and that an acidic, 38 kDa protein present in wild-type eggs was lacking in eggs of the female. In the current study, we first determined the partial amino acid sequence (VANLE) of one of the wellseparated tryptic peptides from the protein, which was found in elongation factor 1 delta (Ef1δ δ δ δ δ) in Xenopus, and finally identified the protein as one of the Ef1δ δ δ δ δ isoforms, Ef1δ δ δ δ δ2, by peptide mass spectrometry. RT-PCR analyses for Ef1δ δ δ δ δ2 and its close homolog Ef1δ δ δ δ δ1 in wild-type oocytes and embryos demonstrated that both transcripts are maternal and Ef1δ δ δ δ δ1 is present more abundantly than Ef1δ δ δ δ δ2 throughout the stages examined. Importantly, the amount of the Ef1δ δ δ δ δ2 transcript per embryo decreased gradually after gastrulation, in accordance with the gradual decrease of the 38 kDa protein per embryo reported in our earlier study. Because pharmacological inhibition of translation induces gastrulation arrest in wild-type embryos, it is reasonable to conclude that the mutant embryos arrest in development due to the lack of Ef1δ δ δ δ δ2 that is indispensable for translation. Thus, the present study provides the first molecular information on the cause of the gastrulation-defective mutation in Amphibia.
embryos. In contrast, the majority of the control antibody-injected eggs gastrulated normally and developed further. These facts strongly indicate that the perturbation of the 38 kDa protein with the antibody induced the developmental arrest of the antibodyinjected embryos at gastrulation.
To clarify the nature of the protein, we have characterized the 38 kDa protein by mass spectrometry. The sequence of oligopeptides independently obtained by enzymatic digestion of the protein separated by 2D PAGE revealed that the protein was elongation factor 1 delta 2 (Ef1δ2) in Xenopus laevis (Minella et al. 1996) . The expression profile of Ef1δ2 was examined, together with Ef1δ1, in wild-type oocytes and embryos by reverse-transcriptase polymerase chain reaction (RT-PCR). The profile of the Ef1δ2 mRNA was comparable to that of the 38 kDa protein reported previously (Tanaka and Ikenishi, 2002) , further indicating that the 38 kDa protein is Ef1δ2.
Results
Partial amino acid sequencing of tryptic peptide fragments and peptide mass spectrometry have identified the 38 kDa protein as eukaryotic translation elongation factor 1 delta 2
To unveil the identity of the 38 kDa protein, first, the 38 kDa protein from cleavage stage embryos separated by 2D PAGE was digested with trypsin in acrylamide gels. Tryptic peptides were fractionated by capillary HPLC and three abundant, well-separated peptides were used to determine partial amino acid sequence. When 5 N-terminal residues were sequenced from each of the peptides, Val-Ala-Asn-Leu-Glu (VANLE) was determined without ambiguity from one peptide, whereas the other two peptides generated mixed signals (Table 1) .
When similar tryptic peptides from the 38 kDa protein were analyzed by peptide mass spectrometry, peptides having monoisotopic molecular masses of 850Da or larger were identified. The molecular mass profile of 34 peptides was subjected to searching a match in three databases (ProFound, Mascot and Aldente at ExPASy, http://ca.expasy.org/; Table 2 ). By summarizing the search results, a total of 14 different peptides out of 34 showed a match to Xenopus laevis eukaryotic elongation factor 1 delta 2 (Ef1δ2; Minella et al., 1996) . Peptide masses corresponding to predicted amino acid positions from 1 to 17, 60 to 72, 168 to 192 and 199 to 211 indicated a potential phosphorylation at one of the Ser or Thr sites (addition of 80Da), an oxidation of Met sites (addition of 16Da) or a combination of both (addition of 112Da; Table 2 ). The mapped peptides covered 57% of the predicted Ef1δ2 amino acid sequence with probability of 0.0091 or greater. Because predicted tryptic fragments from Ef1δ2 between the residues 88 to 167 had smaller molecular masses than 850Da except two at the residues 94 to 109 and 124 to 152, 13% of the predicted Ef1δ2 amino acid sequence could not be matched by this approach. Three predicted polypeptides near the C-terminal end (the residues 222-232, 233-244 and 245-259) and residues 124 to 152 of Ef1δ2 (26% of Ef1δ2) could not be matched to the rest of the peptides from the 38 kDa protein. Peptide mass tolerance larger than 1.2Da could not improve the search result. Perhaps the C-terminal end of Ef1δ2 might be modified by posttranslational modification of proteins, which would prevent the polypeptide from being digested by trypsin. In support of this notion, Ef1δ2 exhibited different electrophoretic mobility from the molecular weight deduced from its predicted amino acid sequence. Further studies are required to determine whether the anomalous electrophoretic mobility of the Ef1δ2 protein in 2D PAGE is ascribed to its post-translational modification.
Ef1δ2 has been identified as a close homologue of Ef1δ1 (Morales et al., 1992) . Both Ef1δ1 and 2 are components of a larger functional protein complex with Ef1β and Ef1γ, which is a substrate of the Cdc2 kinase (Mulner-Lorillon et al., 1994) and acts as a guanine-nucleotide exchange protein (Minella et al., 1996) . As amino acid sequences of Ef1δ1 and 2 share 85.5% of identity and have similar molecular weight (34k and 36kDa, respectively; Minella et al., 1996) , next we have asked if there is a possibility that the 38 kDa protein is Ef1δ1. For the following three reasons, we have excluded this possibility. First, as indicated in Table 2 , 8 out of 14 peptides matched to Ef1δ2 were expected to be generated commonly from Ef1δ1. However, none of the 6 peptides that signify Ef1δ1 (double asterisks in Table 2 ) matched to the rest of the observed peptide masses, whereas 5 out of the 6 peptides that signify Ef1δ2 had matched to the observed peptide masses (p=0.015 by Fisher's exact probability test). Second, based on the independent attempt to sequence tryptic peptides from the 38 kDa protein spot as described above (Table 1) , we could easily identify the peptide sequence VANLE and a deduced sequence from Peptide 3 on Table 1 , Thr-Val-GlnMet-Asp (TVQMD), in two (or three with a modified methionine residue; Table 2 ) of the predicted peptides from both Ef1δ1 and 2. However, the other deduced amino acid sequence from Peptide 2 on Table 1 , Ser-Ser-Asn-Ser-Gln (SSNSQ), was found only in one of the predicted peptides from Ef1δ2. Because the corresponding predicted peptide (1996.07Da) from Ef1δ1 contains SSKSQ, which could be cleaved by trypsin at the C-terminal end of lysine (K) and generated 320.17Da and 1693.91Da fragments, it is less likely that these predicted peptides from Ef1δ1 can be matched to the analyzed peptides from the 38 kDa protein.
Although the unmatched observed peptide mass of 1698.998Da from the 38 kDa protein was closer to the Ef1δ1 peptide of 1693.91Da, the difference of 5.088Da was too large for them to be matched under the current condition. Even if they were matched, the other 5 signature peptides of Ef1δ1 still need to be matched to the observed peptide masses of the 38 kDa protein. Finally, as will be described below, the temporal expression pattern of the Ef1δ1 transcript showed discrepancy from that of the 38 kDa protein (compare Fig. 1B and Fig. 2a in Tanaka and Ikenishi, 2002) . Thus, we have concluded that the 38 kDa protein is not Ef1δ1, but Ef1δ2.
Expression profiles of the Ef1δ δ δ δ δ1 and Ef1δ δ δ δ δ2 transcripts in oocytes and embryos further validate that Ef1δ δ δ δ δ2 is the 38 kDa protein Previously, we showed by immunoblotting using a specific monoclonal antibody against the 38 kDa protein that the protein was present in oocytes (stages I-III mixed, IV, V and VI), unfertilized eggs, fertilized eggs, and embryos at cleavage through tadpole stages examined (see Fig. 2a in Tanaka and Ikenishi, 2002) . Therefore, we have asked if Ef1δ1 or Ef1δ2 transcripts show similar temporal expression patterns in oocytes, eggs and embryos. Although Ef1δ1 and Ef1δ2 are identical through 93% of their sequence, we managed to detect products specific to each gene by semi-quantitative RT-PCR (see Materials and Methods).
Both Ef1δ1 and 2 transcripts were detected in oocytes of all stages examined (stages I-III, IV, V and VI) and unfertilized eggs 
RESULTS OF AMINO ACID SEQUENCING OF N-TERMINAL ENDS OF TRYPTIC PEPTIDES
Amino acid residues sequenced with higher confidence are shown in bold font. a: Observed peptide masses are highlighted in bold when the mass matches with a predicted mass, and by open squares when the match is uniquely found among the peptides from Ef1δ2. Each row represents a unique peptide mass.
b: The list of matched peptide masses was created by combining the search results in Mascot and ProFound databases via ExPASy. Some of the peptides are shown twice due to the potential amino acid modification. Although the peptide DLQSAISK was not identified as a match by the database search at tolerance of 1.2Da, its predicted mass shows only 1.8Da difference from the closest mass observed.
c: The peptide sequence whose mass shows a match with an observed mass is listed as single letters. The position of the amino acid in Ef1δ2 is indicated in parentheses. Five amino acid residues sequenced independently are shown in bold. Asterisks (*) indicate an oxidized methionine (M) or a phosphorylated serine (S), threonine (T) or tyrosine (Y). The phosphorylated T, S or Y residue is marked based on the probability by NetPhosK 1.0 and NetPhos 2.0 servers at ExPASy. The italicized letters indicate amended smaller tryptic peptide fragments when trypsin misses one recognition site, which is the C-terminal end of Lysine (K).
d: Tryptic peptide masses are predicted for Ef1δ1 and Ef1δ2 by PeptideMass at ExPASy. Each row represents a unique peptide mass. RefSeq numbers used to obtain the peptide mass are presented. The predicted mass for peptides smaller than 850Da is not shown because the mass spectrum was measured for peptides larger than 850Da with higher confidence. Matched peptide masses to the observed ones are shown in bold. Three types of predicted peptides were italicized because (1) the peptides of 861.47Da were not considered as a match whereas their predicted mass was relatively closer to the observed peptide mass of 863.272Da, and (2) the peptides of 1968.00Da and 2755.45Da were considered as matches when modifications in amino acid residues were taken into account. For unmatched peptide masses, position of the amino acid in Ef1δ2 is indicated in parentheses. Double asterisks (**) indicate the predicted unique peptide mass from Ef1δ1. Five out of 6 unique peptides larger than 850Da from Ef1δ2 matched with observed peptides, whereas none of unique peptides from Ef1δ1 matched with observed peptides (p=0.015). The matched peptides cover 57% of the predicted Ef1δ2 amino acid sequence. e: The peptide sequence from Ef1δ1 that is closely relative to the matched peptides from Ef1δ2 is shown. Amino acid substitution is underlined. The italicized letters indicate amended smaller tryptic peptide fragments. (Fig. 1B) . It was also observed in the sample of stage 46 without RT (Fig. 1B , the lane "46 RT-"). The product was derived from contaminated genomic DNA, because by direct sequencing it had segments of the sequence corresponding to the Ef1δ2 mRNA separated by an intervening sequence with GTAAGT at the 5' end, and TACTAAC that falls into a consensus sequence, YNYURAY, of the branch site, followed by a polypyrimidine tract and AG at the 3' end (Horowitz and Krainer, 1994 ; Genbank accession numbers GQ379233 and GQ379234). Theoretically, when two templates that can be amplified with the same set of primers that differ in length are present in the same PCR, a shorter product will be amplified more efficiently. By contrast, the amount of the larger PCR product derived from the genomic DNA increased from stage 33/34 onwards, whereas the consistent decrease of the Ef1δ2 expression level was observed. Thus, this result reflects the abundance of the initial Ef1δ2 transcript level in the PCR and the contamination of the genomic DNA itself does not interfere with our interpretation of the results obtained. Finally, we compared the expression profiles of the Ef1δ1 and Ef1δ2 transcripts (Fig. 1B) with that of the 38 kDa protein detected by the specific monoclonal antibody, 9D10 (Tanaka and Ikenishi, 2002) . The abundance of the Ef1δ2 transcript that was present throughout the cleavage stages decreased gradually after gastrulation, in contrast with the significant increase of the copy number of the Ef1δ1 transcript from the neurula stage onward (Fig. 1B) .
On the other hand, the 38 kDa protein that was present at a constant level by the late blastula stage (stage 9) decreased its level steadily from the mid-tailbud stage (stage 28) onward (see Fig. 2a in Tanaka and Ikenishi, 2002 ). These results demonstrate that the temporal change in the amount of the Ef1δ2 transcript was comparable to that of the 38 kDa protein during embryonic development.
In connection with the absence of the 38 kDa protein in the mutant embryos, immunoblotting with 9D10 or a control nonspecific IgM antibody was performed to the protein samples from cleavage stage wild-type and mutant embryos. The 9D10 antibody reacted with the 38 kDa band in the sample from wild-type embryos and with a 25kDa band in the sample from the mutant embryos, whereas the control antibody did not react at all in both samples (Fig. 1C) . The possible origin of the 25kDa band is discussed below (see Fig. 2 ).
Discussion
In the present study, we have shown the first molecular evidence implicating a specific gene in gastrulation arrest observed in the ova-deficient mutant in Xenopus laevis. By analyzing tryptic peptide fragments originated from the 38 kDa protein lacking in the mutant embryos, we could determine the protein to be eukaryotic translation elongation factor 1 delta 2 (Ef1δ2), owing to the accumulation of data for Xenopus genes. This result has been further validated by the similarity of the temporal expression profiles between the Ef1δ2 transcript and the 38 kDa protein detected by the specific antibody (Tanaka and Ikenishi, 2002) . That is, after gastrulation, the amount of the Ef1δ2 transcript per embryo decreased gradually, in accordance with gradual decrease of the amount of the 38 kDa protein per embryo shown in the previous study (Tanaka and Ikenishi, 2002) . By contrast, the amount of the Ef1δ1 transcript per embryo increased significantly with development after gastrulation, showing discrepancy from that of the 38 kDa protein (compare Fig. 1B and Fig. 2a in Tanaka and Ikenishi, 2002) . It is well known that wild-type embryos arrest development at the onset of gastrulation when they are treated with cycloheximide or an inhibitor in protein synthesis prior to the MBT (Hensey and Gautier, 1997) . These arrested embryos exhibit characteristic features of apoptosis including fragmentation of nuclei (Hensey and Gautier, 1997) , which is another phenotype observed in the mutant embryos from the No.65 female (Ikenishi and Tsuzaki, 1988) . Therefore, it is likely that the mutant embryos lacking Ef1δ2 could not initiate de novo protein synthesis, resulting in the developmental arrest at gastrulation, possibly by activation of apoptosis. Similarly, the mutant phenocopy induced in wild-type embryos by injecting the 9D10 antibody (Tanaka and Ikenishi, 2002) might be due to the inhibition of de novo protein synthesis via the perturbation of the Ef1δ2 function. However, the phenocopy was not induced by microinjection of antisense morpholinos against the Ef1δ2 transcript into fertilized wild-type eggs (data not shown). Perhaps the amount of the Ef1δ2 protein present already in the fertilized eggs might be sufficient enough to complete gastrulation.
It is interesting to note that Ef1δ2 exhibits different electrophoretic mobility from the molecular weight deduced from its predicted amino acid sequence. The predicted primary amino acid sequence of Ef1δ2 translated from its cDNA has the molecular weight of 28.63kDa at a pI of 4.6. On the other hand, Ef1δ2 has been identified as a component of 36kDa with a specific polyclonal antibody against a guanine-nucleotide exchange protein complex that is a substrate of the Cdc2 kinase (Mulner-Lorillon et al., 1994) . Anomalous electrophoretic mobility of proteins in PAGE has been ascribed to post-translational modifications, amino acid composition (very hydrophobic, basic or acidic), and transcription or translation attenuation (Klenova et al., 1997) . According to database search, Ef1δ2 has two potential Small Ubiquitin-like Modifier (SUMO) modification sites at the 123rd and 192nd Lysine (K) residues, which typically exhibit the consensus sequence of hKxE, where h and x are a hydrophobic and any amino acid, respectively (Panse et al., 2004) . Because SUMO is a 100-residue protein (Panse et al., 2004) , the molecular weight of a protein ligated with one SUMO will be increased by about 10kDa. Interestingly, the affinity chromatography-based proteomic approach in yeast has identified that eukaryotic translation elongation factor 2 encoded by the Eft2 gene is one of the SUMO targets (Panse et al., 2004) . Unlike ubiquitylation, SUMOylation of target proteins does not lead to proteasomal degradation but can affect diverse functions of the protein, such as subcellular localization, protein/DNA interaction, or enzymatic activity (Panse et al., 2004) .
By immunoblotting with the 9D10 antibody specific to the 38 kDa protein in wild-type embryos, a faint band with the molecular weight of about 25kDa was detected in the sample from the mutant embryos (Fig. 1C) . The difference of the molecular weight between the 25kDa band and without post-translational modification is about 4kDa, which corresponds to 30 to 40 amino acids. Therefore, a plausible scenario to explain the lack of the 38 kDa protein in the mutant embryos may be frame shift at the C-terminal end of Ef1δ2 that causes not only premature termination of translation but also mutation in the site of post-translational protein modification. In fact, insertion of a single nucleotide within the codons encoding one of the putative SUMOylation sites (GCC AAG CTG GAG) or the codon of K192 in Ef1δ2 (AAG; Minella et al., 1996) has potential to translate a polypeptide that supports our result of immunoblotting (Figs. 1C and 2) . Unfortunately, however, it is impossible to validate our model in the mutant embryos directly because the mutant female was dead more than 20 years Fig. 2 . A model to explain the lack of the 38 kDa protein in the mutant embryos. Possible manners of frame shift in Ef1δ2 are shown by insertion of a single nucleotide within a sequence motif, GCC AAG CTG GAG (between 571bp and 582bp from ATG), which is translated into AKLE in amino acid sequence, a predicted SUMOylation site. Insertion of a nucleotide as indicated in the box 1 will substitute K192 in AKLE with other amino acids (XQAG or AXXG). Insertion of a nucleotide as indicated in the box 3 and 4 will leave K192 intact but change the putative SUMOylation site (AKLE) into different contexts (AKXG or AKLX; in the latter case X is other amino acid than E). In either way, these mutations will terminate translation prematurely to generate a polypeptide of 231 amino acids with the predicted molecular weight of 24.9kDa (bolded), which shows consistency with the result of immunoblotting in Fig. 1C . Insertion of a nucleotide as indicated in the box 2 will leave K192 intact as well as the putative SUMOylation site (AKLE), such that this will generate a polypeptide of 231 amino acids modified by SUMOylation. Insertion of T as indicated will terminate translation prematurely to generate polypeptides with the molecular weight shorter than 24.9 kDa. Deletion of any single nucleotide within the codons encoding the motif of AKLE will not terminate translation at the original site but translate a polypeptide of 317 amino acids, no matter how the deletion changes the predicted SUMOylation site. B: C or G or T, N: A or C or G or T, S: C or G, V: A or C or G, Y: C or T.
ago.
It was the first in Amphibia that gastrulation arrest of the o mutant embryos in Ambystoma was restored by microinjection of the unidentified protein component from wild-type eggs (Briggs and Justus, 1968) . The present study clarifies that the 38 kDa protein, which is lacking in the maternal-effect mutant embryos in Xenopus showing a similar phenotype, is the Ef1δ2 protein. It will be interesting to study whether orthologs of Ef1δ2 will play an evolutionarily conserved role in gastrulation of higher vertebrates, such as mouse and human.
Materials and Methods
The African clawed frog Xenopus laevis was used to provide oocytes, eggs and embryos according to the approved protocol to K. I. by the institutional animal care and use committee at the Osaka City University. Collection of wild-type oocytes, eggs and embryos and mutant embryos was done essentially as described previously Tsuzaki, 1988, Tanaka and Ikenishi, 2002) . Oocytes and embryos were staged after Dumont (1972) and Nieuwkoop and Faber (1967) , respectively. No embryo collection from live Xenopus laevis has taken place at the University of Illinois. Unless otherwise noted, chemical reagents were purchased from Wako pure Chemical Industries, Osaka, Japan.
Preparation and characterization of the 38 kDa protein
Two-dimensional (2D) PAGE with protein samples (400~600 μg per gel) from cleavage stage embryos (stage 2-7) was carried out essentially as described previously Tsuzaki, 1988, Tanaka and Ikenishi, 2002) . After staining with 0.1% Coomassie Brilliant Blue-R250 (SigmaAldrich, St. Louis, MO, USA), 50% methanol, 10% acetic acid for 30 min at 22-24ºC, gels were destained with 5% methanol, 7.5% acetic acid overnight at 22-24ºC with agitation. After a brief rinse with distilled water, a spot of the 38 kDa protein, another major protein spot having a similar molecular weight (positive control) and a similar-sized gel piece of protein free area (negative control) were excised with a scalpel from the gels. Gel pieces of those spots (2 x 3 x1 mm 3 each) were pooled separately in a siliconized tube. After boiling for 5 min, the gel pieces in the tubes were quickly chilled on ice, destained 3 times with 100mM NH 4 HCO 3 (pH 8.9), 50% CH 3 CN at 22-24ºC for 30 min each with agitation and dried in a SpeedVac for 30 min. The resultant gel pieces were rehydrated with a solution of sequence grade trypsin (Promega Co., Madison, WI, USA; reconstituted in 1 mM HCl at 0.1 μg/μl, 0.1 μg/gel piece) containing 200 mM NH 4 HCO 3 (pH 8.9) and 0.2% Tween 20, and incubated at 37ºC overnight (Hellman et al., 1995; Rosenfeld et al., 1992) . The reaction was terminated by adding 10% trifluoroacetic acid (TFA) at 1/10 in volume of the reaction mixture (the final concentration was 1%) and the tryptic peptides were eluted 3 times into 60% CH 3 CN, 0.1% TFA at 30ºC for 40 min each with agitation. After reduction to the appropriate volume by evaporation, these samples were used for determining the peptide sequence (Biologica Co., Nagoya, Japan) and for peptide mass spectrometry (MALDI-TOF mass spectrometry at the Proteomics and Mass Spectrometry Unit of the National Institute on Aging, NIH, Baltimore, MD, USA). We estimated that 10 pieces of the 38 kDa protein spots separated by 2D PAGE from a total of 6 mg of the protein sample of cleavage stage embryos (stages 2-7) were equivalent to about 100 pmol of the 38 kDa protein. Protein identification based on the monoisotopic peptide masses was done by searching databases such as ProFound, Mascot and Aldente at ExPASy (http://ca.expasy.org/) by defining the taxon as amphibian or Xenopus laevis.
Semi-quantitative RT-PCR
RNA extraction and first strand cDNA synthesis for polymerase chain reaction (PCR) were done essentially as described previously (Ikenishi and Tanaka, 2000; Tanaka et al., 2008; Tanaka et al., 2006) . Briefly, 5 oocytes at stages IV, V and VI, 5 unfertilized eggs or 5 embryos (stages 1, 7, 9, 12, 18, 23, 28, 33/34, 40 and 46) were pooled for RNA extraction. For oocytes at stages I-III, we pooled 5 oocytes at stages I, II and III together because of the smaller volume of the oocyte at those stages. Quality of extracted RNA was validated with the recovery of 28S and 18S ribosomal RNA on the ethidium bromide-stained agarose gel by electrophoresis. RNA equivalent to one-half of an oocyte (at stages IV-VI), an egg or an embryo at each stage and 1.5 oocytes at stages I-III (1/10 of extracted RNA) was used for cDNA synthesis with SuperScript II (Invitrogen Co., Carlsbad, CA, USA). Likewise, cDNA synthesis without reversetranscriptase (RT) was also performed as negative controls. One-fiftieth of each cDNA was used as a template for the following PCR with Phusion DNA polymerase (New England Biolabs Inc., Ipswich, MA, USA). The primer pairs used are as follows: for Ef1δ1 (469bp), forward, GGTACAAGTCACACCCGCTGC, reverse, AGAGTCCAGCAAGCCAGGG, annealed at 65ºC; for Ef1δ2 (484bp), forward, GGGAGGATGATGATGACGATATCG, reverse, CACCCAGTCGGTACATAAACGAG, annealed at 60ºC. The reverse primer of Ef1δ2 was designed from part of the 3' UTR specific to Ef1δ2. The PCR product for Ef1δ1 but not Ef1δ2 has one BamHI site that gives rise to two fragments of 116 and 353 bp long, which is used to validate the Ef1δ1 PCR product. To further validate specificity of the PCR products, they were directly sequenced by using forward primers for Ef1δ1 or Ef1d2. Similarly, PCR products observed in the sample of stage 46 without RT (Fig. 1B) were sequenced (Genbank accession numbers GQ379233 and GQ379234). Ef1α was used as a loading control (Krieg and Melton, 1985) .
Immunoblotting
Immunoblotting of protein samples of wild-type and mutant embryos with the antibody specific to the 38 kDa protein, 9D10, or a control IgM antibody was carried out as described previously (Tanaka and Ikenishi, 2002) .
